Company
Delphian Therapeutics
- Status
- Operatingas of 2026-09-20
Claim, correct or request removal
Record updated 28 September 2026
About
Delphian Therapeutics is a pioneer in FDA-approved, cannabinoid-based pain relief for hard-to-treat musculoskeletal and neurological conditions. Pain is commonly undertreated in patients of color and is shown to exacerbate adverse health outcomes.
Funding snapshot
- Total raised
- $5.6MSum of rounds, as of 2026-09-20Source (opens in a new tab)
- Latest round
- Grant, $2.9M2024-09-19
Funding rounds
- Grant
- $2.9M2024-09-19, Company stated
- Seed
- $2.7M2024-05-15, Company stated
Products
- Other
- S1-221
Loading relationship preview